A detailed history of Baird Financial Group, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baird Financial Group, Inc. holds 23,168 shares of VRTX stock, worth $10.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
23,168
Previous 53,763 56.91%
Holding current value
$10.8 Million
Previous $25.2 Million 57.24%
% of portfolio
0.02%
Previous 0.05%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $14.1 Million - $15.5 Million
-30,595 Reduced 56.91%
23,168 $10.8 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $830,400 - $1.03 Million
-2,114 Reduced 3.78%
53,763 $25.2 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $4.95 Million - $5.41 Million
-12,134 Reduced 17.84%
55,877 $23.4 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $848,925 - $1.02 Million
2,475 Added 3.78%
68,011 $27.7 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $884,002 - $947,470
2,614 Added 4.15%
65,536 $22.8 Million
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $4.43 Million - $4.95 Million
14,075 Added 28.81%
62,922 $22.1 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $3.22 Million - $3.67 Million
-11,360 Reduced 18.87%
48,847 $15.4 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $193,597 - $216,009
707 Added 1.28%
56,152 $16.3 Million
Q2 2022

Aug 08, 2022

SELL
$234.96 - $292.55 $1.5 Million - $1.86 Million
-6,364 Reduced 10.3%
55,445 $15.6 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $3.15 Million - $3.71 Million
-14,219 Reduced 18.7%
61,809 $16.1 Million
Q4 2021

Feb 09, 2022

BUY
$177.01 - $223.45 $325,344 - $410,701
1,838 Added 2.48%
76,028 $16.7 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $2.12 Million - $2.37 Million
11,661 Added 18.65%
74,190 $13.5 Million
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $1.36 Million - $1.61 Million
7,276 Added 13.17%
62,529 $12.6 Million
Q1 2021

May 13, 2021

BUY
$207.02 - $241.31 $664,120 - $774,122
3,208 Added 6.16%
55,253 $11.9 Million
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $2.2 Million - $2.93 Million
10,616 Added 25.62%
52,045 $12.3 Million
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $1.68 Million - $1.99 Million
6,575 Added 18.86%
41,429 $11.3 Million
Q2 2020

Oct 22, 2020

BUY
$225.48 - $295.8 $449,156 - $589,233
1,992 Added 6.06%
34,854 $10.1 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $2 Million - $2.62 Million
-8,860 Reduced 21.24%
32,862 $8.93 Million
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $733,155 - $909,462
-3,670 Reduced 8.09%
41,722 $9.92 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $2 Million - $2.69 Million
12,017 Added 36.01%
45,392 $9.94 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $250,841 - $282,318
1,509 Added 4.74%
33,375 $5.65 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $854,984 - $988,781
5,194 Added 19.47%
31,866 $5.84 Million
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $945,049 - $1.12 Million
5,772 Added 27.62%
26,672 $4.91 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $2.57 Million - $3.26 Million
16,947 Added 428.71%
20,900 $3.46 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $215,365 - $247,478
-1,284 Reduced 24.52%
3,953 $758,000
Q2 2018

Aug 13, 2018

BUY
$145.72 - $169.96 $37,595 - $43,849
258 Added 5.18%
5,237 $890,000
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $135,378 - $158,177
893 Added 21.86%
4,979 $813,000
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $182,719 - $207,037
1,331 Added 48.31%
4,086 $612,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $15,405 - $16,872
104 Added 3.92%
2,755 $419,000
Q2 2017

Aug 14, 2017

BUY
N/A
2,651
2,651 $342,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Baird Financial Group, Inc. Portfolio

Follow Baird Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.